GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt
· Delayed Price · Currency is EGP 39.56
+0.31 (0.79%)
At close: Mar 27, 2025
GlaxoSmithKline S.A.E Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,991 | 2,240 | 1,823 | 1,812 | 1,993 | Upgrade
|
| Revenue Growth (YoY) | 33.51% | 22.87% | 0.62% | -9.07% | 16.95% | Upgrade
|
| Cost of Revenue | 2,057 | 1,451 | 1,266 | 1,105 | 1,256 | Upgrade
|
| Gross Profit | 933.94 | 789.12 | 557.4 | 706.66 | 737.06 | Upgrade
|
| Selling, General & Admin | 406.75 | 366.27 | 326.91 | 409.16 | 438.5 | Upgrade
|
| Other Operating Expenses | 36.68 | -7.32 | 204.15 | 24.56 | 39.18 | Upgrade
|
| Operating Expenses | 508.07 | 340.29 | 542.07 | 464.5 | 534.55 | Upgrade
|
| Operating Income | 425.87 | 448.83 | 15.33 | 242.16 | 202.51 | Upgrade
|
| Interest Expense | -10.6 | -37.96 | -33.5 | -48.67 | -79.91 | Upgrade
|
| Interest & Investment Income | 78.28 | 42.15 | - | 0.26 | 0.54 | Upgrade
|
| Earnings From Equity Investments | 1 | -18.12 | 12.15 | -9.21 | -19.49 | Upgrade
|
| Currency Exchange Gain (Loss) | -147.63 | -169.75 | 34.53 | -5.39 | -11.91 | Upgrade
|
| EBT Excluding Unusual Items | 346.91 | 265.15 | 28.5 | 179.13 | 91.75 | Upgrade
|
| Impairment of Goodwill | - | -137.65 | -101 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.4 | 0.17 | 5.94 | 0.24 | 0.15 | Upgrade
|
| Legal Settlements | -5.79 | -7.94 | 3.61 | - | - | Upgrade
|
| Pretax Income | 338.72 | 119.74 | -62.94 | 179.37 | 91.9 | Upgrade
|
| Income Tax Expense | 164.74 | 59.26 | 50.87 | 24.74 | 63.75 | Upgrade
|
| Earnings From Continuing Operations | 173.98 | 60.47 | -113.81 | 154.63 | 28.15 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 849.21 | - | - | Upgrade
|
| Net Income to Company | 173.98 | 60.47 | 735.4 | 154.63 | 28.15 | Upgrade
|
| Minority Interest in Earnings | -0 | -0.02 | -0.02 | 0.01 | -0.02 | Upgrade
|
| Net Income | 173.98 | 60.46 | 735.38 | 154.64 | 28.13 | Upgrade
|
| Net Income to Common | 173.98 | 60.46 | 735.38 | 154.64 | 28.13 | Upgrade
|
| Net Income Growth | 187.78% | -91.78% | 375.56% | 449.70% | -80.27% | Upgrade
|
| Shares Outstanding (Basic) | 84 | 84 | 84 | 84 | 84 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 84 | 84 | 84 | 84 | Upgrade
|
| EPS (Basic) | 2.08 | 0.72 | 8.81 | 1.85 | 0.34 | Upgrade
|
| EPS (Diluted) | 2.08 | 0.72 | 8.81 | 1.85 | 0.34 | Upgrade
|
| EPS Growth | 187.78% | -91.78% | 375.56% | 449.70% | -80.27% | Upgrade
|
| Free Cash Flow | -528.49 | 225.2 | 987.26 | 156.43 | -54.84 | Upgrade
|
| Free Cash Flow Per Share | -6.33 | 2.70 | 11.82 | 1.87 | -0.66 | Upgrade
|
| Dividend Per Share | - | 0.750 | - | 0.750 | - | Upgrade
|
| Gross Margin | 31.23% | 35.23% | 30.57% | 39.00% | 36.99% | Upgrade
|
| Operating Margin | 14.24% | 20.04% | 0.84% | 13.36% | 10.16% | Upgrade
|
| Profit Margin | 5.82% | 2.70% | 40.33% | 8.53% | 1.41% | Upgrade
|
| Free Cash Flow Margin | -17.67% | 10.05% | 54.15% | 8.63% | -2.75% | Upgrade
|
| EBITDA | 465.79 | 482.88 | 48.6 | 278.32 | 230.91 | Upgrade
|
| EBITDA Margin | 15.57% | 21.55% | 2.67% | 15.36% | 11.59% | Upgrade
|
| D&A For EBITDA | 39.93 | 34.05 | 33.27 | 36.16 | 28.4 | Upgrade
|
| EBIT | 425.87 | 448.83 | 15.33 | 242.16 | 202.51 | Upgrade
|
| EBIT Margin | 14.24% | 20.04% | 0.84% | 13.36% | 10.16% | Upgrade
|
| Effective Tax Rate | 48.64% | 49.50% | - | 13.79% | 69.37% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.